Compile Data Set for Download or QSAR
Report error Found 1159 Enz. Inhib. hit(s) with all data for entry = 12072
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676209(US20240166635, Example 2a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676212(US20240166635, Example 3b | US20240166635, Example...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676212(US20240166635, Example 3b | US20240166635, Example...)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676212(US20240166635, Example 3b | US20240166635, Example...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676213(US20240166635, Example 4a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676213(US20240166635, Example 4a)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676211(US20240166635, Example 3a | US20240166635, Example...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676211(US20240166635, Example 3a | US20240166635, Example...)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676217(US20240166635, Example 6a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676217(US20240166635, Example 6a)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676233(US20240166635, Example 7a)
Affinity DataIC50: 10nMAssay Description:CDK1/CyclinB kinase inhibitory activity (IC50): 5 μl of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676233(US20240166635, Example 7a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676233(US20240166635, Example 7a)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676233(US20240166635, Example 7a)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676245(US20240166635, Example 8)
Affinity DataIC50: 10nMAssay Description:CDK1/CyclinB kinase inhibitory activity (IC50): 5 μl of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676245(US20240166635, Example 8)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676245(US20240166635, Example 8)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676246(US20240166635, Example 9)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676248(US20240166635, Example 10)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676249(US20240166635, Example 11)
Affinity DataIC50: 10nMAssay Description:CDK1/CyclinB kinase inhibitory activity (IC50): 5 μl of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676249(US20240166635, Example 11)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676250(US20240166635, Example 12)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676250(US20240166635, Example 12)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676253(US20240166635, Example 15)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676255(US20240166635, Example 17)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676256(US20240166635, Example 18a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676260(US20240166635, Example 19a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676260(US20240166635, Example 19a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676262(US20240166635, Example 20a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676264(US20240166635, Example 21a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676268(US20240166635, Example 22a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676268(US20240166635, Example 22a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676270(US20240166635, Example 23a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK1/CyclinB kinase inhibitory activity (IC50): 5 μl of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676270(US20240166635, Example 23a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676276(US20240166635, Example 24a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK1/CyclinB kinase inhibitory activity (IC50): 5 μl of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676276(US20240166635, Example 24a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676276(US20240166635, Example 24a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676276(US20240166635, Example 24a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676276(US20240166635, Example 24a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK7/Cyclin HIMAT1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676276(US20240166635, Example 24a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK9/CyclinT1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676278(US20240166635, Example 25)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676279(US20240166635, Example 26)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676281(US20240166635, Example 27)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676282(US20240166635, Example 28)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676283(US20240166635, Example 29a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676283(US20240166635, Example 29a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676285(US20240166635, Example 30a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676287(US20240166635, Example 31a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676289(US20240166635, Example 32a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676291(US20240166635, Example 33a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1159 total ) | Next | Last >>
Jump to: